Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the COVID-19 pandemic. The development of a high-throughput pseudovirus neutralization assay is critical for the development of vaccines and immune-based therapeutics. In this study, we show that deletion of the cytoplasmic tail of the SARS-CoV-2 spike leads to pseudoviruses with enhanced infectivity. This SΔCT13-based pseudovirus neutralization assay should be broadly useful for the field. ABSTRACT Pseudotyped viruses are valuable tools for studying virulent or lethal viral pathogens that need to be handled in biosafety level 3 (BSL3) or higher facilities. With the explosive spread of the coronavirus disease 2019 (COVID-19) pandemic, the establishment of a BSL2 adapted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus neutralization assay is needed to facilitate the development of countermeasures. Here, we describe an approach to generate a single-round lentiviral vector-based SARS-CoV-2 pseudovirus, which produced a signal more than 2 logs above background. Specifically, a SARS-CoV-2 spike variant with a cytoplasmic tail deletion of 13 amino acids, termed SΔCT13, conferred enhanced spike incorporation into pseudovirions and increased viral entry into cells compared to that with full-length spike (S). We further compared S and SΔCT13 in terms of their sensitivity to vaccine sera, purified convalescent-phase IgG, human ACE2 (hACE2) murine IgG (mIgG), and the virus entry inhibitor bafilomycin A1 (BafA1). We developed an SΔCT13-based pseudovirus neutralization assay and defined key assay characteristics, including linearity, limit of detection, and intra-assay and intermediate assay precision. Our data demonstrate that the SΔCT13-based pseudovirus shows enhanced infectivity in target cells, which will facilitate the assessment of humoral immunity to SARS-CoV-2 infection, antibody therapeutics, and vaccination. This pseudovirus neutralization assay can also be readily adapted to SARS-CoV-2 variants that emerge. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the COVID-19 pandemic. The development of a high-throughput pseudovirus neutralization assay is critical for the development of vaccines and immune-based therapeutics. In this study, we show that deletion of the cytoplasmic tail of the SARS-CoV-2 spike leads to pseudoviruses with enhanced infectivity. This SΔCT13-based pseudovirus neutralization assay should be broadly useful for the field.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, spike, antibody, Neutralization assay, Lentiviral vector, 【초록키워드】 COVID-19, coronavirus disease, IgG, Vaccine, coronavirus, vaccination, pandemic, SARS-COV-2 infection, COVID-19 pandemic, variant, SARS-CoV-2 variant, viral entry, hACE2, Antibody therapeutics, human ACE2, Spread, sensitivity, Humoral immunity, Characteristics, pseudovirus, sera, limit of detection, virus entry, amino acids, SARS-CoV-2 pseudovirus, inhibitor, Critical, Pseudovirus neutralization assay, SARS-CoV-2 spike, target cells, acute respiratory syndrome, Precision, BSL2, BSL3, viral pathogen, cytoplasmic tail, full-length, virulent, murine, pseudovirion, approach, Cell, Biosafety Level 3, log, defined, produced, virus, generate, facilitate, purified, lentiviral, pseudovirus, the SARS-CoV-2, 【제목키워드】 Infectivity, Deletion, tail, increase, the SARS-CoV-2,